+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Relationship between alpha adrenoceptor occupancy and response for the alpha-1 adrenoceptor agonist, cirazoline, and the alpha-2 adrenoceptor agonist, B-HT 933, in canine saphenous vein



Relationship between alpha adrenoceptor occupancy and response for the alpha-1 adrenoceptor agonist, cirazoline, and the alpha-2 adrenoceptor agonist, B-HT 933, in canine saphenous vein



Journal of Pharmacology and Experimental Therapeutics 235(3): 636-643



The relationship between alpha adrenoceptor occupancy and response was investigated for the alpha-1 adrenoceptor agonist, cirazoline, and the alpha-2 adrenoceptor agonist, B-HT 933, in canine saphenous vein, a tissue known to contain both alpha adrenoceptor subtypes. Both cirazoline and B-HT 933 produced dose-dependent vasoconstrictor responses in canine saphenous vein, with the maximum vasoconstrictor response elicited by B-HT 933 being only 75% of that produced by cirazoline. Dissociation constants were obtained for cirazoline (0.61 microM) and B-HT 933 (4.99 microM) for interaction with postsynaptic vascular alpha-1 and alpha-2 adrenoceptors, respectively, by the method of fractional irreversible receptor inactivation using phenoxybenzamine. Based on this information, alpha-1 and alpha-2 adrenoceptor occupancy-response relationships were constructed. The alpha-1 adrenoceptor occupancy-response relationship obtained for cirazoline was approximately 4-fold more favorable than the alpha-2 adrenoceptor occupancy-response relationship for B-HT 933, although both agonists were associated with a significant receptor reserve. The alpha-1 adrenoceptor occupancy-response relationship of cirazoline and the alpha-2 adrenoceptor occupancy-response relationship of B-HT 933 were both rectangular hyperbolas, suggesting that both compounds have high intrinsic efficacy at their respective alpha adrenoceptor subtypes. The results indicate that a receptor reserve exists for the alpha-1 and alpha-2 adrenoceptor-mediated effects of cirazoline and B-HT 933, respectively, and that the alpha adrenoceptor reserve may be significantly larger for postsynaptic vascular alpha-1 adrenoceptors than for postsynaptic vascular alpha-2 adrenoceptors in canine saphenous vein.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 041220058

Download citation: RISBibTeXText

PMID: 2867204


Related references

The prejunctional alpha 2 adrenoceptor antagonist activity of cirazoline a new alpha 1 adrenoceptor agonist on field stimulated guinea pig ileum. Journal of Pharmacy & Pharmacology 35(SUPPL): 91P, 1983

Relationship between alpha 2-adrenoceptor occupancy and response for B-HT 933 in canine saphenous vein. European Journal of Pharmacology 111(2): 267-271, 1985

Functional and biochemical evidence for the lack of cardiac presynaptic alpha-2 adrenoceptor stimulant properties of cirazoline (LD 3098), a potent alpha-1 adrenoceptor agonist in dogs and rats. Journal of Pharmacology and Experimental Therapeutics 223(1): 241-250, 1982

Relationship between alpha adrenoceptor occupancy and response for b ht 933 azepexole in canine saphenous vein. European Journal of Pharmacology 111(2): 267-272, 1985

Alpha 1 adrenoceptor and alpha 2 adrenoceptor response coupling in canine saphenous and femoral veins. Journal of Pharmacology & Experimental Therapeutics 238(1): 131-138, 1986

Central alpha 1-adrenoceptor stimulation functionally antagonizes the hypnotic response to dexmedetomidine, an alpha 2-adrenoceptor agonist. Anesthesiology 75(2): 252-256, 1991

Eugenodilol: a third-generation beta-adrenoceptor blocker, derived from eugenol, with alpha-adrenoceptor blocking and beta2-adrenoceptor agonist-associated vasorelaxant activities. Journal of Cardiovascular Pharmacology 34(1): 10-20, 1999

Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters. Journal of Smooth Muscle Research 45(4): 187-195, 2009

Moxonidine be 5895 is a full agonist at presynaptic alpha 2 adrenoceptor and postsynaptic alpha 1 adrenoceptor sites. British Journal of Pharmacology 90(SUPPL): 27P, 1987

alpha(1)-adrenoceptor subtypes and effect of alpha(1A)-adrenoceptor agonist NS-49 on guinea pig nasal mucosa vasculature. European Journal of Pharmacology 387(1): 73-78, 2000

Postsynaptic alpha adrenoceptor and alpha 2 adrenoceptor subtypes in the human saphenous vein. Blood Vessels 21(3): 147, 1984

Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Molecular Pharmacology 51(1): 36-46, 1997

The effects of ethanol in combination with the alpha 2-adrenoceptor agonist dexmedetomidine and the alpha 2-adrenoceptor antagonist atipamezole on brain monoamine metabolites and motor performance of mice. European Journal of Pharmacology 292(2): 191-199, 1995

The adrenoceptor agonist, SDZ NVI 085, discriminates between alpha 1A- and alpha 1B-adrenoceptor subtypes in vas deferens, kidney and aorta of the rat. European Journal of Pharmacology 224(2-3): 125-136, 1992

The effect of pertussis toxin on alpha 1-adrenoceptor-mediated vasoconstriction by the full agonist, cirazoline, and the partial agonist, (-)-dobutamine, in pithed rats. Fundamental and Clinical Pharmacology 5(1): 11-23, 1991